M

Mount Sinai Health System | The Spine Hospital at Mount Sinai - Department of Surgery

Research site

(Unclaimed)

Location

19 E 98th St, New York, New York, United States of America

Site insights

Top conditions

Top treatments

Resmetirom

Dexamethasone

Natalizumab

Ursodiol

Narazaciclib

Folate

Cisplatin

Alprazolam

Magrolimab

Dupilumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 36 total trials

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)

A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resme...

Enrolling

Non-Alcoholic Fatty Liver Disease

Drug: Resmetirom

A Safety and Effectiveness Prospective Blinded Clinical Study to Validate xBar System as Monitoring Tool for Anastomotic Leaks Detection

Purpose: To validate the safety and effectiveness of xBar monitoring tool for detection of post-operative anastomotic leaks in subjects undergoing re...

Enrolling

Colorectal Surgery

Anastomotic Leak

Diagnostic Test: xBar system

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma

This is an open label Phase 1b/2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or in combination with ultralow dose gemcitabine...

Enrolling

Endometrial Adenocarcinoma

Urothelial Carcinoma

Diagnostic Test: OncoSignature

Drug: ACR-368

COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis

The Synchron motor neuroprosthesis (MNP) is intended to be used in subjects with severe motor impairment, unresponsive to medical or rehabilitative t...

Active, not recruiting

Stroke Brainstem

Spinal Cord Injuries

Device: Motor Neuroprosthesis (MNP)

Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis (SENTRY)

This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve...

Enrolling

Myelofibrosis

Drug: Selinexor

Other: Placebo